Vail's Science Behind series event looks at stem cell treatment for joint pain

Join Walking Mountains Science Center for a discussion on the Science Behind Stem Cell Treatment for Joint Pain on Jan. 16 at 6:30 p.m. ThriveMD medical director Scott Brandt will discuss how stem cells carry huge potential to restore an active and pain-free life.

Autologous (self-derived adult) stem cell therapy is one of the newest and most innovative avenues in regenerative medicine. Brandt will walk attendees through the minimally invasive procedure that works to relieve the pain and limitations of damaged joint cartilage without resorting to an invasive joint replacement surgery.

The procedure involves harvesting a patient's own stem cells found in fat tissue, most often from the abdominal region. The tissue is then prepared in a cell-processing laboratory and injected into the ailing joint an hour later, using fluoroscopic guidance. Once injected, the cells can sense proteins that have been generated from cartilage damage. In response, these cells have the ability to make chondrocytes, which are the type of cells found in healthy cartilage. Then, through chondrogenesis (cartilage cell division), the damaged cartilage can be replaced with healthy cartilage tissue.

Brandt will also discuss the results he is seeing with autologous stem cell therapy and why he prefers using adipose (fat)-derived stem cells.

For the past 15 years, Brandt has specialized in interventional pain management and is now one of the few physicians in the country to be trained in a minimally invasive technique that is helping many patients find alternatives to difficult joint replacement surgery. He is board certified by the America Board of Anesthesiology and has been a diplomat of the American Board of Pain Medicine.

See the rest here:
Vail's Science Behind series event looks at stem cell treatment for joint pain

Gazette.Net: Neuralstem

Physicians, researchers, patients and their advocates in the spinal injury field are keeping a close eye on Rockville biotech Neuralstem as it prepares to launch a Phase 1 safety trial of its stem cell treatment for chronic spinal cord injury.

The Food and Drug Administration approved the trial Monday. Neuralstem plans to conduct the study on eight patients who are completely paralyzed at or below their spinal cord injuries.

Its important that people understand this is very different from other methods that have gone on before, CEO Richard Garr said. This is the real deal. We have compelling data. Cells are surviving, grafting and doing what we would they would do. The FDA go-ahead follows Neuralstems report in October that rats given the stem cell product, NSI-566, seven days after suffering an ischemic stroke showed improvement in motor and neurological tests.

Should this prove to be successful, it will allow for some regeneration of human spinal cord cells and for people to regain function. It will be an incredible breakthrough, with huge implications for the health care market, said Paul Tobin, president and CEO of the National Spinal Cord Injury Association.

More than 10,000 people in the U.S. sustain spinal cord injuries each year, according to the Christopher & Dana Reeve Foundation. About 840,000 people have chronic spinal cord injury. Currently, the best treatment is mitigating secondary damage and providing environments and tools that support patients with these injuries, Tobin said.

While Tobin emphasized that the industry is still far from a cure yet, the Neuralstem treatment could be a tremendous step and appears to be worth exploring.

The primary objective of the study is to determine the safety and toxicity of human spinal stem cell transplants for treating paralysis and related symptoms due to chronic spinal cord injury, according to Neuralstem information. A secondary objective is evaluating graft survival in the transplant site.

All patients will receive six injections in or around the injury site, with the first four patients receiving 100,000 cells per injection and the second four receiving 200,000 cells per injection. The study will follow the patients for six months after the procedures.

Following Mondays announcement, stock analyst Aegis Capital of New York raised its 12-month price target for Neuralstem to $4 from $3.50.

Investors should note the fact that spinal cord injury is the clinical indication that most closely mirrors the situation in the preclinical rat model that yielded the ground-breaking data published in the [trade journal] Cell last year, Aegis wrote in a report Monday.

Read the original post:
Gazette.Net: Neuralstem

Stem Cell Research Wins A Final Legal Battle

(Credit: ANNE-CHRISTINE POUJOULAT/AFP/Getty Images)

By Pat Loeb

PHILADELPHIA (CBS) Local researchers are hailing the announcement that the Supreme Court will not take up the issue of embryonic stem cell research.

The Court refused to review the dismissal of a lawsuit challenging funding for the research.

The decision is good news for researchers at Penn and the Stem Cell Institute of New Jersey, who use stem cells to explore treatment for a wide variety of diseases.

But, ultimately, says Jonathan Moreno of Penns bioethics center, its patients who benefit.

People who have diseases that, if not directly treated, will be much better understood because of access to human embryonic stem cells, says Moreno.

He hopes the decision will remove the stigma that plagued the research as opponents argued the morality of using cells from embryos left over from in vitro fertilization.

(Father Tad Pacholczyk Credit: Pat Loeb)

This raises very significant moral concerns and thats why this has been so much in the eye of the public, he explains.

More:
Stem Cell Research Wins A Final Legal Battle

Stem Cell Surgeons Restore Severely Damaged Baboon Artery

A damaged baboon artery was regenerated with stem cell therapy (Reuters)

Stem cells have been used to completely restore a severely damaged artery, leading to hope that the therapy could be used to fix damaged human organs.

Researchers at the Texas Biomedical Research Institute have shown for the first time that embryonic baboon stem cells can be used to heal a damaged artery that would not have fixed itself.

The artery began to heal three days after being treated with stem cells and was 100 percent restored after two weeks.

John VandeBerg, chief scientific officer at the institute, said: "We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels."

They removed the cells that line the inside surface of segment of the artery and put the stem cells inside the artery.

The stem cell segment was then connected to plastic tubing inside a bioreactor - a device designed to grow cells and tissues. Researchers then pumped fluid through the artery as if blood was flowing through it and the outside of the artery was bathed in fluid to sustain the cells.

Real potential for stem cell medicine

After three days, the inner surface of the stem cell-treated artery had started to regenerate and after 14 days, the artery had been perfectly restored to a fully functional artery.

In order to ensure the artery would not have restored itself, the scientists took a control arterial segment but did not seed it with stem cells - no healing took place.

More here:
Stem Cell Surgeons Restore Severely Damaged Baboon Artery

End to stem cell research challenge doesn't calm funding fears for scientists

Even as they celebrate clearing a legal hurdle, worries of stem cell research grant money evaporating constantly weigh on scientists like Dr. Ted Dawson, whose projects at Johns Hopkins Hospital have helped inform treatment of neurological diseases like Parkinson's and Alzheimer's.

A three-year court battle by two researchers to stop stem cell research using human embryos ended Monday when the Supreme Court declined to review the case. Scientists like Dawson say that frees up grant opportunities and are relieved for now.

"It takes some of the uncertainty out," Dawson said. "It takes us back to a situation where we're hopefully only limited by our creativity, our talent in doing the science and the resources available."

The problem is that more limitations appear likely. Research advocates fear a handful of threats to funding for all types of stem cell research and scientific study in general: the so-called "fiscal cliff," more legal challenges, an eventual new administration in Washington and the possibility of a more competitive peer review process.

Altogether, the hazards have tempered researchers' enthusiasm over the high court's non-decision.

"It's good for research in general," said Dan Gincel, director of the Maryland Stem Cell Research Fund. "It doesn't stop any future presidents from having another executive order to go the other way. If the Supreme Court would have discussed that, it would have put an end to it one way or another."

Embryonic stem cell research has long faced hurdles from those who see it as morally wrong, akin to abortion. Generating a line of the cells requires destroying the embryo. President George W. Bush limited federally funded embryonic stem cell research to only projects using lines developed before August 2001.

President Barack Obama reversed the decision in April 2009, opening up new embryonic stem cell lines to federal funding. But a federal court in Washington, D.C., suspended the change in August 2010 when two scientists sued on behalf of "plaintiff embryos." The opponents lost on appeal. The Supreme Court's refusal to hear the case means the appeals court's ruling in support of the policy stands.

Proponents of the research argue that the cells can be key in the treatment of many diseases because they have the potential to develop into many different cell types in the body. The scientists who challenged the Obama policy, and others like them, argue that research should be limited to using stem cells derived from adult tissue, though some scientists question whether the adult cells have the same potential.

Uncertainty over how courts might have handled appeals of the lawsuit meant few options for stem cell research projects for the past decade. Scientists are reluctant to take on any project for which funding is or might become scarce, Gincel said.

More here:
End to stem cell research challenge doesn't calm funding fears for scientists

Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dd7jnv/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Companies Mentioned

Read the original post:
Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

Stem cells found to heal damaged artery in lab study

Public release date: 10-Jan-2013 [ | E-mail | Share ]

Contact: Joseph Carey jcarey@txbiomed.org 210-258-9437 Texas Biomedical Research Institute

Scientists at the Texas Biomedical Research Institute have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery. These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.

"We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels," said John L. VandeBerg, Ph.D., Texas Biomed's chief scientific officer.

This finding gave VandeBerg and his team the confidence to do complex experiments to find out if these cells could actually heal a damaged artery. Human embryonic stem cells were first isolated and grown in 1998.

The results are presented in a manuscript, co-authored by Texas Biomed's Qiang Shi, Ph.D., and Gerald Shatten, Ph.D., of the University of Pittsburgh, published in the January 10, 2013 issue of the Journal of Cellular and Molecular Medicine.

The scientists found that cells derived from embryonic stem cells could actually repair experimentally damaged baboon arteries and "are promising therapeutic agents for repairing damaged vasculature of people," according to the authors.

Researchers completely removed the cells that line the inside surface from a segment of artery, and then put cells that had been derived from embryonic stem cells inside the artery. They then connected both ends of the arterial segment to plastic tubing inside a device called a bioreactor which is designed to grow cells and tissues. The scientists then pumped fluid through the artery under pressure as if blood were flowing through it. The outside of the artery was bathed in another fluid to sustain the cells located there.

Three days later, the complex structure of the inner surface was beginning to regenerate, and by 14 days, the inside of the artery had been perfectly restored to its complex natural state. It went from a non-functional tube to a complex fully functional artery.

"Just think of what this kind of treatment would mean to a patient who had just suffered a heart attack as a consequence of a damaged coronary artery. And this is the real potential of stem cell regenerative medicinethat is, a treatment with stem cells that regenerates a damaged or destroyed tissue or organ," VandeBerg said.

Read the original here:
Stem cells found to heal damaged artery in lab study

Stem cells found to heal damaged artery in lab study in baboons

Jan. 10, 2013 Scientists at the Texas Biomedical Research Institute in San Antonio have for the first time demonstrated that baboon embryonic stem cells can be programmed to completely restore a severely damaged artery. These early results show promise for eventually developing stem cell therapies to restore human tissues or organs damaged by age or disease.

"We first cultured the stem cells in petri dishes under special conditions to make them differentiate into cells that are the precursors of blood vessels, and we saw that we could get them to form tubular and branching structures, similar to blood vessels," said John L. VandeBerg, Ph.D., Texas Biomed's chief scientific officer.

This finding gave VandeBerg and his team the confidence to do complex experiments to find out if these cells could actually heal a damaged artery. Human embryonic stem cells were first isolated and grown in 1998.

The results are presented in a manuscript, co-authored by Texas Biomed's Qiang Shi, Ph.D., and Gerald Shatten, Ph.D., of the University of Pittsburgh, published in the January 10, 2013 issue of the Journal of Cellular and Molecular Medicine.

The scientists found that cells derived from embryonic stem cells could actually repair experimentally damaged baboon arteries and "are promising therapeutic agents for repairing damaged vasculature of people," according to the authors.

Researchers completely removed the cells that line the inside surface from a segment of artery, and then put cells that had been derived from embryonic stem cells inside the artery. They then connected both ends of the arterial segment to plastic tubing inside a device called a bioreactor which is designed to grow cells and tissues. The scientists then pumped fluid through the artery under pressure as if blood were flowing through it.

The outside of the artery was bathed in another fluid to sustain the cells located there. Three days later, the complex structure of the inner surface was beginning to regenerate, and by 14 days, the inside of the artery had been perfectly restored to its complex natural state. It went from a non-functional tube to a complex fully functional artery.

"Just think of what this kind of treatment would mean to a patient who had just suffered a heart attack as a consequence of a damaged coronary artery. And this is the real potential of stem cell regenerative medicine -- that is, a treatment with stem cells that regenerates a damaged or destroyed tissue or organ," VandeBerg said.

To show that the artery couldn't heal itself in the absence of stem cells, the researchers took a control arterial segment that also was stripped of the cells on its interior surface, but did not seed it with stem cells. No healing occurred.

Stains for proteins that indicate functional characteristics showed that the healed artery had completely normal function and could do everything that a normal artery does in a healthy individual.

See the rest here:
Stem cells found to heal damaged artery in lab study in baboons